ScandiDos AB operates with a business model focused on the development and provision of advanced quality assurance solutions for radiation therapy. The company aims to improve patient safety and treatment accuracy by offering innovative and reliable products. ScandiDos AB's portfolio includes the Delta4 Phantom+ system, which enables precise measurements of radiation doses delivered during cancer treatments. By continuously refining their product offerings and collaborating with leading radiation therapy centers, ScandiDos AB strives to enhance treatment quality and facilitate the advancement of cancer care.

ScandiDos AB is primarily active in the healthcare industry.

The main competitors of ScandiDos AB in the market include Varian Medical Systems, Elekta AB, and Sun Nuclear Corporation. These companies also specialize in the development and manufacturing of advanced radiation therapy quality assurance solutions, similar to ScandiDos AB. However, ScandiDos AB stands out with its innovative technologies and products, such as the world-renowned Delta4 system. With its commitment to delivering accurate and reliable quality assurance solutions, ScandiDos AB continues to compete effectively in the market, gaining recognition and trust from customers worldwide.

ScandiDos AB, a renowned Swedish company, boasts a rich history and background. Established in [insert year], ScandiDos AB has become a leading player in the field of quality assurance solutions for modern radiation therapy. Throughout its journey, the company has revolutionized the medical industry by offering advanced radiation measuring systems and software, ensuring accurate and safe cancer treatments. With a strong commitment to innovation and research, ScandiDos AB continually pioneers cutting-edge technologies that enhance patient care and treatment outcomes. Today, ScandiDos AB stands as a globally recognized name, trusted by medical professionals worldwide for its exceptional contributions to radiation therapy.

ScandiDos AB, a renowned stock company, has achieved remarkable milestones throughout its journey. The company has established itself as a leader in the field of advanced quality assurance systems for radiotherapy, revolutionizing the industry. ScandiDos AB has successfully developed and deployed innovative products like Delta4, providing accurate and efficient dosimetry measurement solutions. Additionally, the company has expanded its global presence through strategic partnerships and collaborations, reinforcing its position as a trusted provider of cutting-edge technology in radiation therapy. ScandiDos AB's commitment to excellence and continuous advancements have made them a preferred choice in the industry, ensuring better patient care and treatment outcomes.

ScandiDos AB is primarily present in Sweden and the European region.

ScandiDos AB represents a strong commitment to innovation, quality, and customer satisfaction. The company believes in continuous improvement and strives to deliver cutting-edge solutions in the field of radiation therapy quality assurance. With a focus on precision and accuracy, ScandiDos AB aims to ensure the highest standards of radiation treatment planning and delivery. Their corporate philosophy revolves around providing reliable and effective tools for healthcare professionals to enhance patient safety and optimize treatment outcomes. By investing in research and development, ScandiDos AB remains dedicated to advancing the field of radiation dosimetry and improving the overall quality of cancer care.

Converted at the current exchange rate, the ScandiDos share trades at 0.08 EUR (0.87 SEK).

The company ScandiDos AB is a leading provider of diagnostic and monitoring systems for radiation therapy. The company was founded in Sweden in 2002 and has since become a global market leader. ScandiDos AB is headquartered in Uppsala, Sweden, and operates sales and service centers in the USA, Europe, and Asia. The business model of ScandiDos AB is based on the development and sale of diagnostic and monitoring systems for radiation therapy. The company offers a wide portfolio of products, including the Delta4 system for real-time monitoring of radiation dose and the Compass system for precise patient positioning during radiation therapy. The Delta4 system from ScandiDos AB is a unique monitoring system that measures and monitors the radiation dose in real-time during radiation therapy. It is the world's first system to deliver radiation dose at all levels of the patient, enabling fast and accurate dose monitoring. The system is used in hospitals worldwide and is appreciated by radiation therapists and medical physicists alike. The Compass system from ScandiDos AB is a precise positioning system that ensures the patient is in the correct position and does not move during radiation therapy. The system uses automatic and continuous monitoring technology to monitor the patient's position throughout the entire radiation therapy session. This allows for precise and effective radiation therapy. Other products from ScandiDos AB include the Solo system for monitoring radiation dose in individual sessions and the ArcCheck system for control and monitoring of beam shape in arc radiation. ScandiDos AB also has a strong service business, offering its customers technical support and training programs. The company works closely with its customers to ensure they can effectively use ScandiDos AB's products and services. ScandiDos AB has developed a range of tailored training programs for its customers, including individual and group training. Overall, ScandiDos AB's business model is focused on offering high-quality and innovative products and services that enable medical professionals to provide precise and effective radiation therapy. The company aims to improve radiation therapy and provide patients with better treatment and healing prospects.

The revenue of ScandiDos is 54.22 M SEK. This figure is based on current financial data and reflects the company's business performance.

The profit of ScandiDos is -3.44 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ScandiDos is currently -14.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ScandiDos stock.

The price-to-sales ratio (P/S) of ScandiDos is currently 0.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ScandiDos stock.

The Eulerpool Quality Score for ScandiDos is 2/10.

The ISIN of ScandiDos is SE0005768124. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ScandiDos is A112AF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ScandiDos is SDOS.ST. The ticker symbol is used to trade ScandiDos shares on the stock exchange.

ScandiDos paid dividends every year for the past 0 years.

ScandiDos is assigned to the 'Health' sector.

The dividends of ScandiDos are distributed in SEK.